Genea Stem Cells (GSC): 25 New Disease Specific Pluripotent Stem Cell Lines Placed on the National Institutes of Health (NIH) Registry

Published: Jan 14, 2013

SYDNEY, Australia--(BUSINESS WIRE)--Genea Stem Cells Pty Ltd (GSC), a supplier and developer of disease-specific human stem cells, today announced that 25 of its disease specific embryonic pluripotent stem cell lines have been placed on the USA National Institutes of Health (NIH) human stem cell registry. These embryonic stem cell lines are now all available commercially for use in medical research.

Back to news